Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | NX-5948 |
Synonyms | |
Therapy Description |
NX-5948 is a chimeric targeting molecule (CTM) comprised of a BTK binding element linked to Cereblon (CRBN), which potentially induces degradation of BTK and inhibition of tumor growth (Blood 2021 138 (Supp 1):2251). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NX-5948 | NX5948|NX 5948 | BTK inhibitor 36 | NX-5948 is a chimeric targeting molecule (CTM) comprised of a BTK binding element linked to Cereblon (CRBN), which potentially induces degradation of BTK and inhibition of tumor growth (Blood 2021 138 (Supp 1):2251). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BTK C481S | diffuse large B-cell lymphoma | predicted - sensitive | NX-5948 | Preclinical - Cell culture | Actionable | In a preclinical study, NX-5948 inhibited Btk signaling and proliferation of a diffuse large B-cell lymphoma cell line expressing BTK C481S in culture (Cancer Res (2023) 83 (7_Supplement): 2850). | detail... |
BTK V416L | diffuse large B-cell lymphoma | predicted - sensitive | NX-5948 | Preclinical - Cell culture | Actionable | In a preclinical study, NX-5948 inhibited Btk signaling and proliferation of a diffuse large B-cell lymphoma cell line expressing BTK V416L in culture (Cancer Res (2023) 83 (7_Supplement): 2850). | detail... |
BTK L528W | diffuse large B-cell lymphoma | predicted - sensitive | NX-5948 | Preclinical - Cell culture | Actionable | In a preclinical study, NX-5948 inhibited Btk signaling and proliferation of a diffuse large B-cell lymphoma cell line expressing BTK L528W in culture (Cancer Res (2023) 83 (7_Supplement): 2850). | detail... |
BTK T474I | diffuse large B-cell lymphoma | predicted - sensitive | NX-5948 | Preclinical - Cell culture | Actionable | In a preclinical study, NX-5948 inhibited Btk signaling and proliferation of a diffuse large B-cell lymphoma cell line expressing BTK T474I in culture (Cancer Res (2023) 83 (7_Supplement): 2850). | detail... |
BTK C481S | diffuse large B-cell lymphoma activated B-cell type | predicted - sensitive | NX-5948 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, NX-5948 treatment resulted in degradation of BTK C481S and inhibited proliferation of an activated B-cell type diffuse large B-cell lymphoma (ABC-DLBCL) cell line harboring BTK C481S in culture and inhibited tumor growth in a cell line xenograft model (Blood 2021 138 (Supp 1):2251). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05131022 | Phase I | NX-5948 | Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | Recruiting | USA | NLD | GBR | 0 |